A New Target for Severe Hip Arthritis: Treating the Bone Beneath the Cartilage

A New Target for Severe Hip Arthritis: Treating the Bone Beneath the Cartilage
For many years, osteoarthritis was described as a disease of “worn-out cartilage.” We now know the condition is more complex.
Hip osteoarthritis affects the entire joint. This includes the cartilage, joint lining, surrounding tissues, and the bone beneath the cartilage. That deeper layer is called subchondral bone.
A major 2026 study by Philippe Hernigou and colleagues suggests that treating this bone directly with bone marrow concentrate may help some patients preserve their natural hip and delay hip replacement.
Why This Study Is Important
Most bone marrow concentrate treatments for arthritis have been injected into the joint space. This is called an intra-articular injection.
In patients with advanced osteoarthritis, prior studies of intra-articular bone marrow concentrate have failed to show meaningful or statistically significant improvement. One possible reason is that an injection into the joint may not adequately treat disease inside the bone. This was an inconvenient truth often ignored by the inexperienced or profit-focused practitioners in the field, but it actually kept me recommending hip replacements instead of regenerative medicine to most of the patients that I evaluated – until just a few months ago.
The Hernigou study changed everything, and now I have real hope for many of my patients with severe hip osteoarthritis.
You see, instead of placing bone marrow concentrate inside the joint, the researchers injected it directly into the femoral head—the ball-shaped bone at the top of the thigh bone. This is called an intraosseous injection.
The goal was to treat the abnormal bone beneath the damaged cartilage.
What Is Bone Marrow Concentrate?
Bone marrow concentrate, or BMC, is made from a patient’s own bone marrow.
Bone marrow contains platelets, growth factors, signaling proteins, and several types of cells involved in healing. These include mesenchymal stem cells, often called MSCs.
MSCs may help regulate inflammation and support tissue repair. Researchers believe that their main effects come from the signals they release—not from simply turning into new tissue.
How Was the Study Performed?
The study followed 434 hips for up to 15 years.
The researchers compared two matched groups:
- 217 hips received intraosseous bone marrow concentrate.
- 217 hips received conservative care, such as exercise, physical therapy, weight management, pain medication, and activity changes.
The groups were matched by age, sex, cause of arthritis, and arthritis severity.
The patients were relatively young, with an average age of about 42. Each patient had already undergone a hip replacement on one side. The study followed the arthritic hip on the opposite side.
For the treatment group, bone marrow was collected from the back of the pelvis, which is actually a very easy and comfortable procedure when done by an experienced practitioner. The bone marrow was then concentrated in a centrifuge and the number of mesenchymal stem cells in each sample was measured in order to determine the dose of cells each patient received. About 20 milliliters of bone marrow concentrate was then injected into the femoral head under fluoroscopic guidance.
The main question was simple:
How many patients would need a hip replacement on the treated or observed side during the next 15 years?
The 15-Year Results
The difference between the groups that received bone marrow concentrate into the hip bone vs the group that was treated conservatively was substantial.
After 15 years, less than half as many hip bones that were injected with bone marrow concentrate needed to be replaced.
The difference appeared early and continued over time:
Follow-up periodIntraosseous BMCConservative care5 years4.6% had hip replacement28.6% had hip replacement10 years12.0% had hip replacement35.9% had hip replacement15 years16.1% had hip replacement40.1% had hip replacement
The study therefore found an association between intraosseous (in the bone) BMC treatment and a lower risk of progressing to hip replacement.
What Happened in Severe Osteoarthritis?
The results in severe arthritis are especially important.
Previous studies using injections only inside the joint have generally been less encouraging for patients with advanced osteoarthritis. Once severe joint-space loss and major bone changes are present, an intra-articular injection is not likely to provide lasting pain relief.
In the patients who got intraosseous BMC, the 15-year hip replacement rates were:
- Mild arthritis: 4.6% with BMC versus 18.5% with conservative care
- Moderate arthritis: 23.6% with BMC versus 58.3% with conservative care
- Severe arthritis: 35.1% with BMC versus 67.6% with conservative care
Patients with severe arthritis still had the highest risk of needing surgery. Intraosseous BMC did not make advanced arthritis disappear, and it did not prevent every hip replacement.
However, the difference between the treated and control groups suggests that directly treating the subchondral bone may be clinically important—even in some patients with severe disease.
This is what makes the study pivotal. It shifts the treatment target from the joint fluid and cartilage surface to the living bone beneath the cartilage.
Cell Dose Also Appeared to Matter
The study found a strong dose-response relationship.
Patients were divided into three groups based on the dose of MSCs delivered:
- Low dose: fewer than 94,000 colony forming units-fibroblast (CFU-Fs), which is a measure of dose.
- Intermediate dose: 94,000 to 115,000 CFU-Fs
- High dose: more than 115,000 CFU-Fs
At 15 years, hip replacement rates were:
- 38.8% in the low-dose group
- 10.0% in the intermediate-dose group
- 1.4% in the high-dose group
Higher cell doses were associated with longer survival of the natural hip. Patients in the two higher-dose groups had no hip replacements during at least the first six years after treatment.
This finding supports an important principle in orthobiologics: technique and dose matter.
Bone marrow collection methods can affect the number of useful cells obtained. Large-volume draws from a single location dilute the sample with peripheral blood. This is the harvest technique used by the “big box” nationally-advertised regenerative medicine franchises. The researchers used small-volume draws from several locations to reduce this dilution, which is the same technique used at LifeStem Regenerative Medicine.
The final result depends on more than simply performing a slapdash “stem cell procedure” as quickly and profitably as possible. It depends on how the marrow is collected, processed, and delivered. It requires the thoughtful, precise, optimized approach taken by a physician who cares about their patient’s outcome.
Why Treat the Bone?
Subchondral bone is not just a platform holding up the cartilage. It is a living and active part of the joint.
In osteoarthritis, this bone may develop:
- Abnormal remodeling
- Poor blood flow
- Increased pressure
- Small areas of damage
- Bone marrow edema (swelling)
- Cysts
- Inflammatory changes
Unlike cartilage, subchondral bone contains nerves and can be an important source of pain.
An injection inside the joint mainly exposes the joint lining and cartilage surface to the treatment. An intraosseous injection places the bone marrow concentrate directly into the damaged bone-cartilage region.
This may help change the local environment, reduce harmful inflammatory signaling, and support healthier bone remodeling. These possible mechanisms remain under study.
Pain, Function, and Medication Use
Among BMC-treated patients who did not undergo hip replacement, the average Harris Hip Score improved from 76 to 90 points. Pain accounted for much of this improvement.
In the control group, the average score fell from 77 to 71 points.
Pain medication use also decreased in the treated group. At the final assessment, only about 19% of the BMC-treated patients who had avoided hip replacement reported using pain medication. All remaining control patients reported medication use.
The authors reported no adverse events related to the BMC treatment. However, all medical procedures carry associated risks. Ask your doctor about the risks for your unique situation prior to undergoing one of these procedures.
Important Limitations
These findings are promising, but the study does not prove that intraosseous BMC will prevent hip replacement in every patient.
This was a retrospective, non-randomized study from a single center. Patients were matched, but they were not randomly assigned to treatment. There was also no sham injection group.
Other differences between the groups may have influenced the decision to proceed with hip replacement. The study population was also younger than the typical population seeking care for hip osteoarthritis.
Larger randomized and multicenter studies are still needed.
What Does This Mean for Patients?
Intraosseous bone marrow concentrate may offer a joint-preserving option for carefully selected patients with hip osteoarthritis.
The strongest results were seen when:
- Treatment occurred before the disease became too advanced.
- An adequate dose of mesenchymal stem cells was delivered.
- The procedure directly targeted the abnormal subchondral bone.
- The hip did not have major structural problems, such as significant developmental dysplasia.
Patients with severe arthritis may still benefit, but their risk of eventually needing hip replacement remains higher. A detailed evaluation by a physician specializing in orthobiologics is needed to determine the extent of cartilage loss, bone damage, structural deformity, and other causes of hip pain.
The Bottom Line
This study represents an important step forward because it looked beyond injections placed only inside the joint.
After 15 years, patients treated with intraosseous bone marrow concentrate had a lower hip replacement rate than matched patients receiving conservative care. The study also found better results when higher doses of stem cells were delivered.
The findings support a more complete view of osteoarthritis: successful treatment may require addressing the bone beneath the cartilage, not only the joint space itself.
If you have hip osteoarthritis and are considering regenerative treatment, choose your clinic carefully. Before moving forward, ask these important questions:
- Will a medical or osteopathic doctor with advanced training in regenerative medicine personally evaluate my condition?
- Will the physician carefully review my imaging to determine whether I am a good candidate and discuss my realistic chances of success?
- Does the clinic use a bone marrow harvesting technique designed to collect an adequate cell dose?
- Does the physician have the training, experience, imaging guidance, and specialized equipment needed to perform an intraosseous injection safely and precisely?
- Will the clinic put my safety and treatment goals ahead of making a sale?
At LifeStem Regenerative Medicine, your evaluation is performed by a medical doctor who specializes in treating musculoskeletal pain with regenerative medicine. We take the time to review your symptoms, medical history, physical examination, imaging studies, joint structure, and overall health. We then explain whether you are a reasonable candidate, what alternatives may be available, and what you can realistically expect from treatment.
If you decide to proceed, the entire LifeStem team will focus on your safety, comfort, and the careful planning and performance of your procedure. Our goal is to give you the best possible opportunity for a successful outcome—without pressure, exaggerated promises, or a sales pitch.
Schedule a complimentary consultation with LifeStem Regenerative Medicine in Houston to learn whether an orthobiologic treatment may be appropriate for you.
This article is for educational purposes only and is not medical advice. Results vary, and no treatment can guarantee pain relief, tissue healing, or avoidance of surgery.
Reference: Hernigou P, Centeno CJ, Berger DR, Dodson E, Murphy MB. Intraosseous bone marrow concentrate delays total hip arthroplasty in osteoarthritis: A fifteen year matched cohort study with dose-response analysis. International Orthopaedics. 2026;50:1617–1626. doi:10.1007/s00264-026-06908-x
